SCHEMBL12605787

SCHEMBL12605787

C/C=C/c1c(-c2ccc(C(C)(C)C)cc2)[nH]c2nccnc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3A P49840 17/20 0.49
▸ GSK3B P49841 17/20 0.49
▸ CDK1 P06493 16/20 0.49
▸ MAPK8 P45983 3/20 0.49
▸ CDK2 P24941 3/20 0.49
▸ AURKA O14965 2/20 0.49
▸ MAP4K4 O95819 2/20 0.49
▸ PAK4 O96013 2/20 0.49
▸ ABL1 P00519 2/20 0.49
▸ FYN P06241 2/20 0.49
▸ RET P07949 2/20 0.49
▸ KDR P35968 2/20 0.49
▸ CDK8 P49336 2/20 0.49
▸ ACVR1 Q04771 2/20 0.49
▸ PTK2 Q05397 2/20 0.49
▸ LRRK2 Q5S007 2/20 0.49
▸ ALK Q9UM73 2/20 0.49
▸ CDC7 O00311 1/20 0.49
▸ PLK4 O00444 1/20 0.49
▸ CHEK1 O14757 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1779142 1.00 GSK3A (0.49) GSK3AGSK3BCDK1MAPK8CDK2
SCHEMBL1779140 1.00 GSK3A (0.49) GSK3AGSK3BCDK1MAPK8CDK2
SCHEMBL1777171 0.79 GSK3A (0.68) GSK3AGSK3BCDK1MAPK8CDK2
SCHEMBL12205754 0.75 GSK3A (0.82) GSK3AGSK3BCDK1MAPK8CDK2
SCHEMBL3100624 0.74 GSK3A (0.70) GSK3AGSK3BCDK1MAPK8CDK2
SCHEMBL1777968 0.73 GSK3A (0.53) GSK3AGSK3BCDK1MAPK8CDK2
Iodide SCHEMBL5618949 0.71 GSK3A (0.60) GSK3AGSK3BCDK1MAPK8CDK2
SCHEMBL1777265 0.70 GSK3A (0.56) GSK3AGSK3BCDK1MAPK8CDK2
SCHEMBL1777803 0.70 GSK3A (0.55) GSK3AGSK3BCDK1MAPK8CDK2
SCHEMBL1778992 0.70 GSK3A (0.62) GSK3AGSK3BCDK1MAPK8CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943616-B2 Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders AVENTIS PHARMACEUTICALS INC. (US) 2011-05-17 — — US disclosed
EP-2233486-A1 Azaindoles Aventis Pharma Limited (GB) 2010-09-29 — — EP disclosed
Send feedback